Hepatologia

RNA-based therapies in liver metabolic diseases.

Gut. 2025 Aug; 74(Aug):1514-1527. doi: 10.1136/gutjnl-2023-331742. pii: e331742.

British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.

Gut. 2025 Aug; 74(Aug):1364-1409. doi: 10.1136/gutjnl-2024-333171. pii: e333171.

Frailty and physical activity: are all physical activity variables equal?

The journals of gerontology. Series A, Biological sciences and medical sciences. 2025 Jul; 80(Jul):doi: 10.1093/gerona/glaf125. pii: glaf125.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to Treatment.

Annual review of medicine. 2026 Jan; 77(Jan):103-115. doi: 10.1146/annurev-med-050324-124753. pii: .

Beyond the mucosa: The emerging role of endoscopic ultrasound in the diagnosis and management of inflammatory bowel disease.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 Jan; 58(Jan):13-22. doi: 10.1016/j.dld.2025.10.027. pii: S1590-8658(25)01186-7.

The ``ABC'' of genetics in cholestatic liver diseases.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 Jan; 58(Jan):1-4. doi: 10.1016/j.dld.2025.06.027. pii: S1590-8658(25)00896-5.

Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD.

Gut. 2026 Jan; 75(Jan):382-397. doi: 10.1136/gutjnl-2025-336268. pii: .

GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.

Mayo Clinic proceedings. 2025 Dec; doi: 10.1016/j.mayocp.2025.09.017. pii: S0025-6196(25)00551-8.

Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.

JAMA. 2026 Jan; 335(Jan):163-174. doi: 10.1001/jama.2025.19615. pii: .

From protocol to precision: The evolving diagnosis of hepatorenal syndrome.

Journal of hepatology. 2026 Jan; 84(Jan):e19-e21. doi: 10.1016/j.jhep.2025.07.027. pii: S0168-8278(25)02393-1.

Pharmacological Management for Prevention and Treatment of Posthepatectomy Liver Failure.

Digestive surgery. 2025 ; 42():301-311. doi: 10.1159/000548937. pii: .

Evaluation of Patients with Liver Disease before Nonhepatic Surgery.

Clinics in liver disease. 2025 Aug; 29(Aug):563-582. doi: 10.1016/j.cld.2025.03.003. pii: S1089-3261(25)00019-4.

Vascular Liver Disease: Emerging Concepts in the Sinusoidal Space.

Clinics in liver disease. 2025 Aug; 29(Aug):545-561. doi: 10.1016/j.cld.2025.03.008. pii: S1089-3261(25)00024-8.

The Liver in Heart Failure and Adults with Congenital Heart Disease.

Clinics in liver disease. 2025 Aug; 29(Aug):527-544. doi: 10.1016/j.cld.2025.03.005. pii: S1089-3261(25)00021-2.

Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Clinics in liver disease. 2025 Aug; 29(Aug):503-525. doi: 10.1016/j.cld.2025.03.004. pii: S1089-3261(25)00020-0.

Hepatotoxicity of Chemotherapy and Immune Checkpoint Inhibitors.

Clinics in liver disease. 2025 Aug; 29(Aug):483-501. doi: 10.1016/j.cld.2025.03.006. pii: S1089-3261(25)00022-4.

The Liver in Hematologic Malignancies: Lymphoma, Leukemia, and Myeloma.

Clinics in liver disease. 2025 Aug; 29(Aug):469-481. doi: 10.1016/j.cld.2025.03.009. pii: S1089-3261(25)00025-X.

The Liver in Sepsis.

Clinics in liver disease. 2025 Aug; 29(Aug):453-467. doi: 10.1016/j.cld.2025.04.002. pii: S1089-3261(25)00027-3.

Bacterial Infections Involving the Liver.

Clinics in liver disease. 2025 Aug; 29(Aug):431-452. doi: 10.1016/j.cld.2025.03.002. pii: S1089-3261(25)00018-2.

The Liver in Diabetes and Metabolic Syndrome.

Clinics in liver disease. 2025 Aug; 29(Aug):407-429. doi: 10.1016/j.cld.2025.04.003. pii: S1089-3261(25)00029-7.

Telomere Disorders and the Liver.

Clinics in liver disease. 2025 Aug; 29(Aug):385-405. doi: 10.1016/j.cld.2025.03.001. pii: S1089-3261(25)00017-0.

Amyloidosis and the Liver.

Clinics in liver disease. 2025 Aug; 29(Aug):371-384. doi: 10.1016/j.cld.2025.03.007. pii: S1089-3261(25)00023-6.

Liver Diseases in Inborn Errors of Metabolism: Bridging Pediatric and Adult Hepatology.

Clinics in liver disease. 2025 Aug; 29(Aug):347-369. doi: 10.1016/j.cld.2025.04.001. pii: S1089-3261(25)00026-1.

Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality.

Nutrition, metabolism, and cardiovascular diseases : NMCD. 2025 Jun; 35(Jun):103965. doi: 10.1016/j.numecd.2025.103965. pii: S0939-4753(25)00119-X.

Extracellular Vesicles and Micro-RNAs in Liver Disease.

Seminars in liver disease. 2025 Jun; 45(Jun):167-179. doi: 10.1055/a-2494-2233. pii: .

Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study.

Hepatology (Baltimore, Md.). 2025 Sep; 82(Sep):612-625. doi: 10.1097/HEP.0000000000001231. pii: .

The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2025 Jun; 31(Jun):815-831. doi: 10.1097/LVT.0000000000000589. pii: .

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

Journal of hepatology. 2025 Feb; 82(Feb):315-374. doi: 10.1016/j.jhep.2024.08.028. pii: S0168-8278(24)02508-X.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology (Baltimore, Md.). 2023 Dec; 78(Dec):1922-1965. doi: 10.1097/HEP.0000000000000466. pii: .

A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

Journal of hepatology. 2023 Jun; doi: 10.1016/j.jhep.2023.06.003. pii: S0168-8278(23)00418-X.

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.

Journal of hepatology. 2023 Jul; 79(Jul):181-208. doi: 10.1016/j.jhep.2023.03.010. pii: S0168-8278(23)00185-X.

EASL Clinical Practice Guidelines on hepatitis delta virus.

Journal of hepatology. 2023 Aug; 79(Aug):433-460. doi: 10.1016/j.jhep.2023.05.001. pii: S0168-8278(23)00317-3.

EASL Clinical Practice Guidelines on acute-on-chronic liver failure.

Journal of hepatology. 2023 Aug; 79(Aug):461-491. doi: 10.1016/j.jhep.2023.04.021. pii: S0168-8278(23)00244-1.

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.

Journal of hepatology. 2023 Nov; 79(Nov):1254-1269. doi: 10.1016/j.jhep.2023.06.002. pii: S0168-8278(23)00417-8.

ACG Clinical Guideline: Focal Liver Lesions.

The American journal of gastroenterology. 2024 Jul; 119(Jul):1235-1271. doi: 10.14309/ajg.0000000000002857. pii: .

Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.

Drug safety. 2024 Apr; 47(Apr):321-332. doi: 10.1007/s40264-024-01399-4. pii: .

AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.

Gastroenterology. 2024 Jan; 166(Jan):202-210. doi: 10.1053/j.gastro.2023.10.016. pii: S0016-5085(23)05143-0.

AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Gastroenterology. 2023 Oct; 165(Oct):1080-1088. doi: 10.1053/j.gastro.2023.06.013. pii: S0016-5085(23)00881-8.

Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.

JAMA. 2026 Jan; 335(Jan):163-174. doi: 10.1001/jama.2025.19615. pii: .

Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD.

Gut. 2026 Jan; 75(Jan):382-397. doi: 10.1136/gutjnl-2025-336268. pii: .

Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management.

Nature reviews. Gastroenterology & hepatology. 2026 Jan; doi: 10.1038/s41575-025-01159-4. pii: .

From protocol to precision: The evolving diagnosis of hepatorenal syndrome.

Journal of hepatology. 2026 Jan; 84(Jan):e19-e21. doi: 10.1016/j.jhep.2025.07.027. pii: S0168-8278(25)02393-1.

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes.

Journal of clinical and experimental hepatology. 2026 ; 16():103411. doi: 10.1016/j.jceh.2025.103411. pii: 103411.

Beyond the mucosa: The emerging role of endoscopic ultrasound in the diagnosis and management of inflammatory bowel disease.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 Jan; 58(Jan):13-22. doi: 10.1016/j.dld.2025.10.027. pii: S1590-8658(25)01186-7.

The ``ABC'' of genetics in cholestatic liver diseases.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2026 Jan; 58(Jan):1-4. doi: 10.1016/j.dld.2025.06.027. pii: S1590-8658(25)00896-5.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to Treatment.

Annual review of medicine. 2026 Jan; 77(Jan):103-115. doi: 10.1146/annurev-med-050324-124753. pii: .

GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.

Mayo Clinic proceedings. 2025 Dec; doi: 10.1016/j.mayocp.2025.09.017. pii: S0025-6196(25)00551-8.

Interpreting abnormal liver blood test results.

BMJ (Clinical research ed.). 2025 Nov; 391(Nov):e082648. doi: 10.1136/bmj-2024-082648. pii: .